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pKaThe inﬂuenza A/M2protein is a homotetrameric single-pass integralmembraneprotein encodedby the inﬂuenza
A viral genome. Its transmembrane domain represents both a crucial drug target and a minimalistic model
system for transmembrane proton transport and charge stabilization. Recent structural and functional studies
of M2 have suggested that the proton transport mechanism involves sequential extraviral protonation and
intraviral deprotonation of a highly conserved His37 side chain by the transported proton, consistent with a
pH-activated proton shuttle mechanism. Multiple tautomeric forms of His can be formed, and it is not known
whether they contribute to the mechanism of proton shuttling. Here we present the thermodynamic and
functional characterization of an unnatural amino acid mutant at His37, where the imidazole side chain is
substituted with a 4-thiazolyl group that is unable to undergo tautomerization and has a signiﬁcantly lower
solution pKa. The mutant construct has a similar stability to the wild-type protein at pH 8 in bilayers and is
virtually inactive at external pH 7.4 in a semiquantitative liposome ﬂux assay as expected from its lower
sidechain pKa. However when the external buffer pH is lowered to 4.9 and 2.4, the mutant shows increasing
amantadine sensitive ﬂux of a similarmagnitude to that of thewild type construct at pH 7.4 and 4.9 respectively.
These ﬁndings are in line with mechanistic hypotheses suggesting that proton ﬂux through M2 is mediated by
proton exchange from adjacent water molecules with the His37 sidechain, and that tautomerization is not
required for proton translocation. This article is part of a Special Issue entitled: Viral Membrane Proteins —
Channels for Cellular Networking.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The inﬂuenza A/M2protein (M2) is amulti-modular 97 residue inte-
gralmembrane protein encoded by the viral genome that forms a paral-
lel homotetramer in the viral envelope and is required for multiple
functions in viral replication [1]. Its transmembrane domain mediates; POPC, 1-Palmitoyl-2-oleoyl-
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ights reserved.passive, N-terminal acid activated, pH-regulated proton transport that
is inhibited by the antiviral agents amantadine and rimantadine in in-
creasingly rare sensitive circulating inﬂuenza strains [2,3]. M2 is thus
of interest not only as a clinically important drug target but also as a
model system of structurally minimalistic [4], highly regulated trans-
membrane proton transport with a high degree of charge stabilization
in the pore [5].
The proton transport properties of M2 have been under extensive
study for several decades, and our understanding of its mechanism of
conduction and charge stabilization has been recently accelerated
with the advent of high-resolution TMdomain structures and improved
solid state NMR techniques [1]. Mutagenesis experiments have shown
that two pore-lining residues in the M2 transmembrane domain
(M2TM), His37 and Trp41 are required for proton selectivity and
N-terminal acid activation, respectively [6,7]. Earlymechanistic hypoth-
eses suggested that M2 may function as an electrostatic gate, where
sequential protonation of His37 residues opens the pore for proton
conduction across water wires in a Grotthuss style mechanism [8];
however, this mechanism is inconsistent with functional studies show-
ing that M2 proton transport saturates at a much lower rate than the
diffusion-limited process that this mechanism would predict [9].
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sequential Cys mutants of the transmembrane domain suggested that
M2 conducts protons as a histidine shuttle [10], where the His37 imid-
azole groups are protonated fromwatermolecules within the extraviral
aspect of the pore and deposit their protons ontowatermolecules in the
intraviral aspect of the pore. This mechanism suggests that the conduc-
tion speed limit is likely determined by the pKa of theHis37 residue, and
speciﬁcally the deprotonation step which is predicted to be much
slower than the protonation step [11]. This mechanism is consistent
with the saturating behavior of proton transport seen in functional
studies [9,12].
Recently determined high resolution structures of the M2 trans-
membrane domain at a variety of pH values in micelles [5,13–15] sug-
gested that the pore populates a pH dependent conformational
ensemble [16] with the extraviral Val27 gate becoming progressively
more closed at low external pH, restricting extraviral proton access to
His37, and the intraviral Trp41 gate becoming progressively more
open, allowing greater access to His37 from the intraviral side to sug-
gest a transporter-like conduction cycle where conformational changes
alternately expose the cargo binding site to either side of the mem-
brane. A ﬂuorescence quenching study with the full length protein
reconstituted in bilayers [12] supported the notion of a pH-dependent
conformational equilibrium at the transmembrane domain, and good
ﬁts to externally acquired functional data could be achieved with an
activated, cyclic kinetic mechanism involving rapid conformational
transitions between two structural variants with the overall rate-
limiting step being His37 residue deprotonation on the intraviral aspect
of the pore [12]. More recent NMR studies imply a role for backbone
conformational transitions in facilitating proton conduction, but there
is no experimental evidence that these steps are rate-limiting [17,18].
Pending more detailed experimental investigation of the require-
ment for backbone conformational changes in the M2 conduction
mechanism, the focus remains on the interaction of the permeant pro-
ton with the His37 tetrad as the critical process in proton transport,
with the proton release step postulated to be rate-limiting. Several
hypotheses exist as to the sidechain-level mechanistic transitionsmedi-
ating this interaction.
Prior to the existence of atomic-resolution M2 structures, Pinto and
colleagues used mutagenesis to derive a structural model suggesting a
conduction cycle of His37 protonation and deprotonationwith interme-
diate steps of sidechain imidazole ring-ﬂipping or tautomerization [10].
This hypothesis was supported by a high-resolution crystal structure
of the M2TM tetramer in detergent micelles obtained at intermediate
pH,where the tetrad of His37 sidechains (the “His box”) is oriented par-
allel to the transmembrane axis and surrounded by a highly ordered
hydrogen-bonded water network presumed to stabilize the permeant
proton and the protonated His-box intermediates [5]. The “His box”
ring-ﬂip mechanism was also supported by recent solid state NMR
characterization of M2 reconstituted in native-like membranes, where
His37 ring ﬂip, protonation, and deprotonation were shown to take
place on roughly the same timescale of 105 s−1 and were signiﬁcantly
inhibited by the addition of amantadine [17]. No evidence for rapid
inter-tautomer exchange at the His37 imidazoles as initially postulated
by Pinto et al. [10] was seen in other NMR experiments conducted by
this group [19]. Of note, the protonation, ring ﬂip and deprotonation
timescales described in Ref. [17] are 1–2 orders of magnitude faster
than M2 conduction rates calculated in vesicle assays performed by
multiple groups, [4,20–22] suggesting that the protein either does not
attain its speed limit in the conditions employed in vesicle assays or
that other steps may also limit its conduction rate.
A second hypothesis for proton permeation suggests that the His37
tetrad partitions into a dimer of dimers stabilized by low-barrier inter-
sidechain hydrogen bonds [23] which forms the resting state in the
transport mechanism. This dimer is disrupted by the permeant proton,
and the protonated imidazolium intermediate is stabilized by a nearby
Trp41 sidechain. This mechanism is supported by a M2 tetramerstructure obtained through solid-state NMR spectroscopy in bilayers
and by ab initio modeling [18,24], and does not rule out imidazole
ring ﬂipping as part of proton transport. While NMR experiments by
other investigators did not observe this low-barrier hydrogen bonded
imidazolium dimer [25], more recent work suggests that both mecha-
nisms may play a role in M2 proton conduction [26].
Here we extend our understanding of the M2 proton transport
mechanism with a functional characterization of an unnatural amino
acid mutant of M2 at position 37, where the imidazole heterocyclic
ring is replacedwith a 4-thiazole group that has a signiﬁcantly lower so-
lution pKa (2.55 vs ~6.5) and is incapable of tautomerization (Fig. 1).
Previously published chemical rescue experiments by Pinto et al. indi-
cated that M2 His37Gly regained function with added buffer compo-
nents that sterically and electronically resembled imidazole [27]. We
ﬁnd that the thiazole-substituted M2TM construct shows similar stabil-
ity to wild-type peptide in pH 8 in bilayers, and that a longer construct
involving the TMdomain and the C-terminal amphiphilic helix is largely
inactive in a liposome ﬂux assay at pH 7.4 as predicted by the low pKa of
the thiazole side chain. The mutant construct shows a pH-dependent
pattern of increasing amantadine sensitive proton ﬂux at pH 4.9 and
2.4 that is similar in magnitude to ﬂux through the wild type construct
at pH 7.4 and 4.9 respectively, suggesting that proton conduction
throughM2 is highly tuned to the pKa at the His37 side chain, and, as in-
dicated in recent ssNMR experiments, does not necessarily require
His37 side chain tautomerization [19].
2. Materials and methods
2.1. Peptide preparation and puriﬁcation
Peptides (M2 constructs of length 19–46 and 19–62 using the A/
Udorn/72 sequence with the C50S mutation; 19-NH2-CNDSSDPLV
VAASIIGILHLILWILDRL-(-CONH2-46)-FFKSIYRFFEHGLKRG-CONH2-62)
were synthesized by Fmoc solid-phase chemistry as C-terminal
carboxamides, and were N-terminally amidated to protect the Cys
19 sidechain. Peptides were synthesized on an Applied Biosystems
433A synthesizer, or, for the longer constructs, manually using a CEM
Mars microwave heated reactor, with frequent reaction monitoring.
Fmoc-protected L-4-thiazolylalanine was purchased from Synthetech
(Albany, OR) and used without further puriﬁcation in place of Fmoc-
His(Trt)-OH at position 37 in themutant peptide. Peptideswere cleaved
from the resin and puriﬁed using RP-HPLC according to previously
described procedures [4,28].
2.2. Thermodynamic stability studies of M2(19–46) constructs using
thiol–disulﬁde equilibria
Thermodynamic studies of tetramer stability of the M2(19–46) WT
and mutant constructs in DLPC bilayers were performed according to
a previously described protocol [28].
Small unilamellar vesicles were prepared by codissolving M2TM
19–46/triﬂuoroethanol stock solutions with the appropriate amount
of DLPC (Avanti Polar Lipids) from a stock solution in ethanol. The sol-
vent was evaporated under a stream of nitrogen, and the protein/
phospholipid ﬁlm was kept overnight under high vacuum to remove
all traces of solvent. The dry peptide/phospholipid ﬁlms obtained
were then hydrated in buffer (0.1 M Tris·HCl/0.2 M KCl/1 mM EDTA,
pH 8.6), vortexed, and sonicated to clarity by using a bath sonicator
(Laboratory Supplies, Hicksville, NY). The concentration of peptide
(20 μM) was kept constant while varying the phospholipid concentra-
tion to attain the desired peptide/phospholipid mole ratios (typically
between 1:100 and 1:1500).
Reversible disulﬁde formation was initiated by adding oxidized
glutathione (GSSG) and reduced glutathione (GSH) at varying ratios to
the samples as previously described [29]. The time required for the
equilibration of the samples was determined by analyzing aliquots of
Fig. 1. Nature of His37 unnatural amino acid substituent. A. Three-dimensional representation of the M2TM domain with His37 sidechains highlighted in orange and Trp41 sidechains
highlighted in purple, (PDB ID: 3LBW). B. Chemical structure and pKa values of histidine and 4-thiazolylalanine.
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HPLC. To ensure equilibration between the vesicles, the samples were
freeze-thawed every hour during the equilibration, using a dry ice–
acetone bath for freezing and a bath sonicator during thawing, followed
by sonication to clarity. After equilibration, the reactionswere quenched
by lowering the pH.
The components of the equilibrium mixtures were analyzed by
reverse-phase HPLC. They typically consisted of a mixture of three spe-
cies corresponding to the thiol-free peptide, mixed disulﬁde of peptide
with GSH, and disulﬁde-bonded peptide. These species were identiﬁed
by using matrix-assisted laser desorption ionization-time of ﬂight MS.
A small amount of the reaction mixture was used to determine the
total free thiol content at the end of the reaction by using Ellman's
reagent, 5,5′-dithiobis(2-nitrobenzoic acid). The amount of covalent
dimerwas calculated from the integratedHPLCpeak areas of the present
species in the chromatograms by using the software supplied with the
HPLC.
The data obtained from thiol–disulﬁde exchange measurements
were ﬁt to a fully cooperative monomer–tetramer equilibrium as previ-
ously described [28] where the fully reduced tetrameric species could
subsequently be partially (one disulﬁde bond) and then fully oxidized
(two disulﬁde bonds) at equilibrium. A baseline correction was
employed as previously described [28].
Raw data in this assay were reproducible within 5% and the curve
ﬁtting pKtet was reproducible to within one unit (one order of magni-
tude) in multiple ﬁt trials.
2.3. Liposome ﬂux assay
2.3.1. Determination of proton ﬂux through M2 constructs incorporated
into liposomes using a pH-sensitive ﬂuorescent dye
Functional studies of the WT M2(19–62) constructs and the
thiazolyl histidinemutantwere performed largely according to the pro-
tocol described in Ref. [4].
2.3.1.1. Sample preparation. Lipid ﬁlms consisting of 4:1:2 POPC:POPG:
cholesterol (25 μmol total) were made by nitrogen or argon gas stream
evaporation ofmixed freshly opened chloroform stocks of the phospho-
lipids (POPC and POPG, 25 mg/mL, Avanti Polar Lipids, Alabaster, AL)
and a fresh chloroform stock of powder cholesterol (25 mg/mL, Sigma
Aldrich, St. Louis, MO). The resulting lipid ﬁlms were dried on a lyophi-
lizer for at least two hours. Only Teﬂon, metal and glass components
were used to handle the chloroform stocks to prevent leaching of plas-
ticizers from plastic components.
Peptide concentration was quantiﬁed by using absorbance at 280 nm
in an ethanol stock, with ε280 for M2(19–62) of 6990 M−1 cm−1.
Lyophilized peptides (as triﬂuoroacetate salts from HPLC puriﬁcation)
were dissolved in ethanol and the fragment concentration was
determined. Stocks were maintained on dry ice or at −80 °C untiluse. Peptide in ethanol in an amount of 25 nmol monomer was added
to a lipid ﬁlm (target 1:1000 monomer:lipid ratio); additional ethanol
was added to a total volume of approximately 300 μL. For control lipo-
somes, only ethanol was added. The mixture was vortexed to dissolve
the dried lipid, then immediately dried under an argon stream.
The resulting ﬁlm was immediately hydrated with 990 μL “K” buffer
(50 mM K2SO4, 15 mM KxPO4 pH ~7.5) by vortexing for 2 min. The
mixturewas frozen on dry ice and thawed. 10 μL of 100 mMof the ﬂuo-
rescent pH indicator hydroxypyrene trisulfonic acid trisodium salt
(HPTS, pyranine from Invitrogen) was then added, and the mixture
vortexed. Unilamellar liposomes were formed by 10 freeze–thaw
cycles (dry ice/ethanol and 37 °C water bath) and sized by repeated
passage through 100 nm polycarbonate ﬁlter membranes (Whatman,
Piscataway, NJ) in a mini-extruder (Avestin, Ottawa, Canada). Lipo-
somes were then dialyzed overnight in a 10 K MWCO Pierce Slide-A-
Lyzer cassette against 1.8 L of “K” buffer pH 7.40 (adjusted with
H3PO4 or KOH) with 5 g Amberlite XAD-4 resin (Supelco, Bellefonte,
PA) added to bind unincorporated dye. Dialyses were performed at
4 °C. Liposomes were stored at 4 °C for up to a week following the
completion of dialysis.2.3.1.2. Proton ﬂux assay. Experiments were performed using an Aviv
ATF-105 spectroﬂuorometer (Aviv Biomedical, Lakewood, NJ) in a
1 × 1 cm Hellma (Plainview, NY) QS ﬂuorescence cell, thermostated
at 18 °C. The ratiometric pH indicator HPTS (pyranine, pKa ~ 7.22)
was used to determine intraliposomal pH. The ratio of ﬂuorescent signal
of the deprotonated form (excitation 460 nm, emission 515 nm, “F−”)
to the pH-independent isosbestic point (excitation 417 nm, emission
515 nm, “Fiso”) as a function of pH was used to calibrate the assay and
was largely independent of the presence of liposomes. For all samples
measured with amantadine, liposomes were pre-mixed with 100×
aqueous amantadine HCl (Sigma Aldrich, St. Louis, MO) in a 100:1 v/v
ratio and allowed to interact for three hours so as to achieve equilibrium
binding.2.3.1.3. Assay buffers. 2.5 mL of assay buffer (50 mM Na2SO4, 15 mM
NaxPO4 pH 7.4, 4.9, or 2.4 adjusted with H3PO4 or NaOH, “Na buffer”)
was added to the ﬂuorescence cuvette. To the assay “Na” buffer was
added 37.5 μL of 1 M p-xylene bis-pyridinium bromide (DPX;
Invitrogen, Carlsbad, CA), a membrane impermeable quencher of
pyranine ﬂuorescence to restrict measured signal to intraliposomal
HPTS. To trigger proton ﬂux, 3.5 μL of 18 μM valinomycin acting as po-
tassium ionophore to trigger a transmembrane potential (Fluka/Sigma
Aldrich, St. Louis, MO) was added from an ethanol stock. Valinomycin
was added at a predicted ~1:1 valinomycin:functional tetramer ratio.
Where amantadine inhibitionwas tested, 25 μL of 100× aqueous aman-
tadine hydrochloride was also added to the assay buffer.
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DPX, valinomycin and drug as indicated) was allowed to equilibrate at
18 °C for 5 min in the ﬂuorometer cell holder. Liposomes (~20 μL)
were injected into the cuvette containing assay buffer from a 1 mL
Hamilton (Reno, NV) glass syringe ﬁtted with a repeat-dispensing sys-
tem. Injections (at t = 0 s) were performed through an adapter in the
ﬂuorometer cell holder cover that enabled immediate data acquisition
following injection. The sample in the cuvette was vigorously stirred
during the experiment. From t = 0 s, kinetic data monitoring the
deprotonated form of HPTS (F−, ex 460 nm, em 515 nm, bandwidths
2 nm) were collected for approximately 50 s at one second intervals.
The ﬁrst three seconds following injection were omitted from analysis
to allow for full mixing of the sample. At t = ~90 s, kinetic data moni-
toring the pH-independent isosbestic point of HPTS (Fiso, ex 417 nm,
em 515 nm, bandwidths 2 nm) were collected for approximately 20 s
at one second intervals. An excitation wavelength scan (ex 480–
380 nm, em 515 nm, bandwidths 2 nm) was performed at the conclu-
sion of each experiment for secondary conﬁrmation of the result.
Experiments on each condition were performed in triplicate.
2.3.1.5. Liposome Flux AssayData Analysis. Themeasured isosbestic kinet-
ic signal (Fiso, ex 417 nm, em 515 nm) was averaged to a single value
when experiments were performed at a bathing buffer pHout of 7.4,
and each data point from the deprotonated HPTS signal kinetic (F−, ex
460 nm, em 515 nm) was divided by the isosbestic signal average to
obtain a signal ratio (deprotonated:isosbestic) as a function of time.
During experiments done at pHout 4.9 and 2.4, noticeable decreases
in the isosbestic signal of HPTS, Fiso (ex 417 nm, em 515 nm) were ob-
served compared to runs performed at pHout 7.4, which suggests that
some dye may be leaking out of the liposomes at low pH conditions,
or that the isosbestic wavelength may not be set with sufﬁciently high
precision. To correct for this effect, the Fiso signal for a given set of
liposomes determined in low pH experiments (e.g. control, WT,
ThiazolylAla) was linearly normalized to its value determined from ex-
periments performed at pHout 7.4, since a similar volume of liposomes
was added for each run.
More speciﬁcally, the time-averaged Fiso signals (obtained at ~90–
120 s following experiment start) from triplicate runs under each
condition were further averaged amongst themselves, and ratios of
these values obtained at pH 4.9 vs. pH 7.4 and pH 2.4 vs. pH 7.4 were
calculated. Recording of the Fiso signal began approximately 90
(t = 90–120 s) seconds following the start of each run, and the F−
signal was recorded for the ﬁrst ~45 s (t = 0–45 s) of each run. The
time-averaged Fiso signal for each low pH runwas extrapolated to earli-
er timepoints with the following operation:
Fiso t;pH Xð Þð Þ ¼ Fiso t¼90 to 120;pH Xð Þð Þ 1þ
AvgFiso pH7:4ð Þ
AvgFiso pH Xð Þð Þ
−1
 
1− t
90
  
:
The F−/Fiso ratios at each time point were then averaged between
the three independent experiments run for each condition, and the
averaged ratios were used to calculate the intraliposomal pH according
to a previously determined HPTS pH calibration curve. Plots of these
ratios (F−/Fiso) vs. time following the above corrections are shown in
supplementary Figs. S1–S3 with error bars reﬂecting the associated
standard deviations from triplicate runs. Excellent reproducibility was
observed in these assays as shown.
Intraliposomal pH (− log[H+free]) vs. time was converted to total
intraliposomal [H+] vs time (including H+ bound to buffer) by using
an estimate of the internal buffering capacity [30] assuming an
intraliposomal [phosphate] of 15 mM, and negligible contribution to
buffering capacity by the dye given its much lower concentration.
Total intraliposomal [H+] vs. time was converted to the total
intraliposomal proton count vs. time through multiplication by NA and
intraliposomal volume estimated from dynamic light scattering mea-
surements (described below) assuming no phospholipid loss duringpreparation and a single phospholipid surface area of 6.3 × 10−19 m2.
Experiments with tracer amounts of radiolabeled lipid show that signal
loss during typical preparations is b10%.
The initial number of total protons at t = 3 s was subtracted from
successive measurements, and the result was divided by the number
of peptide tetramers delivered per experiment, as estimated by in-
tegration of the 280 nm protein peak from chromatography of
proteoliposome samples on an analytical RP-HPLC column (see below).
Results for protein-free control liposomes were adjusted for differ-
ences in surface area with fragment-containing liposomes, and were
normalized for the degree of protein reconstitution observed for the
fragment in each panel (i.e. the difference in total H+ vs. time traces
for the control liposomes was divided by the same number of peptide
tetramers as determined for the corresponding protein-containing sam-
ple shown in each panel).2.3.2. Estimate of liposome peptide reconstitution
Liposome samples were mixed in a 2:1 ratio with a lysis buffer
containing 150 mM nOG and 150 mM Tris pH 8. 100 mM TCEP HCl
(~6% v/v) was added to all samples. The mixture was then injected
onto an analytical C4 RP-HPLC column and elutedwith a linear gradient
of 2:1 isopropanol:acetonitrile with 0.1% TFA and water with 0.1% TFA.
Peptide incorporation was quantiﬁed using a standard curve (four cali-
bration points ﬁttedwith linear regression, R2 = 0.95) using extinction
coefﬁcients of 6990 M−1 cm−1 at 280 nmwavelength for bothWT and
thiazole constructs. In subsequent calculations, random peptide orien-
tationwithin the bilayerwas assumed and the calculated tetramer pop-
ulation was divided by two to reﬂect this.2.3.3. Determination of liposome volume and surface area
Liposome radii were determined using a Wyatt (Santa Barbara, CA)
DynaPro dynamic light scattering instrument at 25 °C. Liposomes
were diluted ~1:1000–1:10,000 into pre-ﬁltered “K” buffer. Measure-
ments were performed in triplicate for each sample, and the radius dis-
tribution peak maxima were averaged. Standard deviations of these
measurements were within 5%.
Volumes and surface areas were determined based on the averaged
measured radius. The software of the instrument was set for analysis
based on a Rayleigh sphere model, and the solvent model was set to
phosphate buffered saline.3. Results
3.1. M2(19–46) His37(4-thiazolyl)Ala mutant shows similar tetramer
stability to wild type peptide in bilayers
We ﬁrst set out to determine whether substitution of the sterically
similar yet electronically distinct 4-thiazole heterocycle for the imidaz-
ole at position 37 signiﬁcantly perturbed the thermodynamic stability of
the M2TM tetramer. Thermodynamic studies of tetramer stability of
M2(19–46) WT and His37(4-thiazolyl)Ala mutant construct were per-
formed in DLPC bilayers using a previously described thiol–disulﬁde
equilibrium method [28] where tetramer stability is determined by
the relative amount of Cys19-mediated peptide dimer formation as a
function of redox balance set by varying concentrations of glutathione
and oxidized glutathione dimer in the experimental buffer. The pres-
ence of the C-terminal helix (residues ~50–62) in addition to the TMdo-
main signiﬁcantly enhances M2 tetramer stability (unpublished data),
therefore shorter constructs and a relatively thin bilayer were used for
this experiment so that some amount of dissociated proteinwas present
to enable calculation of the equilibrium constant. Longer constructs
such as M2(19–62) and/or thicker bilayers such as POPC result in virtu-
ally completeM2 tetramerization and thus cannot be used to determine
dissociation constants.
Table 1
Thermodynamic stabilities of wild type and M2His37(4-thiazolyl)Ala mutant
constructs. pKtet is − log(Ktet), where Ktet is the tetramer dissociation
equilibrium constant.
Construct pKtet at pH 8
M2(19–46) wild type 8.4
M2(19–46) 4-thiazolylalanine 7.8
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46) WT and His37(4-thiazolyl)Ala mutant constructs in DLPC bilayers
are shown in Table 1.
The data show that at pH 8 in bilayers, thewild-type andmutant con-
structs have roughly similar tetramer stabilities (within an order ofmag-
nitude), indicating that the introduction of the unnatural amino acid
does not substantially destabilize the tetrameric assembly of the protein.
This ﬁnding paves the way for functional experiments to assess the
impact of the mutation on proton transport, activation, and inhibition.3.2. M2(19–62) His37(4-thiazolyl)Ala is inactive at pHout 7.4 but shows
increasing amantadine sensitive activity at pHout 4.9 and 2.4 comparable
to activity of wild-type construct at pH 7.4 and 4.9 respectively
The results for M2(19–62) proteoliposomes in our semiquantitative
ﬂux assay (Fig. 2A) show that the construct forms a functional,
amantadine-sensitive tetramer at bathing extraliposomal buffer pH
values of 7.4 and 4.9. An initial transport rate of approximately 1 proton
per second per tetramer is observed at pHout 7.4, and increases to ap-
proximately 3 protons per second per tetramer at pHout 4.9. The initial
transport rate into WT peptide liposomes at pHout 2.4 could not be cal-
culated from the post-mixing ﬂux curve because of very rapid liposome
acidiﬁcation during the 3 s sample mixing period and prior to data
acquisition. Based on intraliposomal buffer pKa and estimates of pre-
mixing intraliposomal pH, it is estimated to be ~15–20 protons per sec-
ond per tetramer during the mixing process. This rate is signiﬁcantly
lower than expected from other estimates of maximum M2 current
in the literature [20–22,31], and may reﬂect dissociation or inactivation
of the wild type protein at very acidic pH values [21,32]. Flux limitation
by the amount of valinomycin used (~30 nM, active tetramer:
valinomycin ~1:1) must also be considered but is less likely given the
high (104) per second turnover rate of valinomycin [33] and saturating
potassium concentrations. No inhibitory effect of amantadine on ﬂux
through the wild type construct was observed at bathing buffer pH of
2.4 (Fig. S2).Fig. 2. Semiquantitative determination of inward proton ﬂux throughM2 19–62 proteoliposom
symbols, apo construct; outline symbols, with amantadine inhibition. A. Wild-type construct. BThe M2(19–62) thiazolylalanine construct (Fig. 2B) was largely
inactive at pH 7.4, as may be expected given the much lower pKa of
this sidechain as compared to histidine (in solution, ~2.55 vs 6.5 respec-
tively). However, progressive proton ﬂux activation was observed at
pH 4.9 and especially pH 2.4, where signiﬁcant proton currents (~1.5
per second per tetramer) were observed. At all pH values tested, the
currents were almost fully amantadine sensitive, indicating a native-
like conformation of the tetramer and its N-terminal aqueous pore
where amantadine binds.
4. Discussion
The proton transport mechanism through M2 remains of interest
not only for guiding design of new inhibitors of amantadine-resistant
variants of the protein [13,34,35], but also from the perspective of a
minimalistic model system for regulated, selective transmembrane
charge transport and stabilization [1,18].
Since the initial postulation of two mechanistic hypotheses for M2
proton transport, the His37 electrostatic gate [8] and the His37 proton
shuttle [10], the last several years have brought about an increasingly
reﬁned understanding of the structural and dynamic underpinnings
that give rise to the functional complexity exhibited by M2. Overall,
our understanding of M2 proton transport today [1,11,18,19,25] is
remarkably consistent with the previously proposed proton shuttle
mechanism [10] although it can now be interpreted within a wealth of
atomic-level structural data increasingly derived in native-like lipid
bilayers [18,19].
Our ﬁndings presented here further reﬁne our mechanistic under-
standing of M2 proton transport by reinforcing its dependence on
His37 side chain protonation and deprotonation as determined by its
pKa. In keeping with earlier results from chemical rescue experiments
by Pinto et al. [27], we have been able to engineer a sterically similar
yet electronically distinct His37 mutant variant with a markedly lower
sidechain pKa that preserves tetramer stability in bilayers but predict-
ably shifts proton ﬂux activation to a lower extraviral pH range where
wild-type protein begins to lose some of its physiological properties
such as amantadine sensitivity [21].
The unnatural 4-thiazole group, in addition to its steric resemblance
of imidazole and lower pKa, is, by contrast with imidazole, incapable of
undergoing tautomerization. Our ﬁndings of native-like proton currents
through the mutant construct at an appropriately lowered extra-
liposomal pH range indicate that proton transport throughM2 can pro-
ceed independently of His37 tautomerization, presumably relying on
side chain motion alone as suggested in recent ssNMR experiments
[17–19].es following control liposome ﬂux subtraction at bathing buffer pH values as shown. Solid
. ThiazolylAla mutant at position 37.
1087A.L. Polishchuk et al. / Biochimica et Biophysica Acta 1838 (2014) 1082–1087Finally, the 4-thiazolylAla mutant construct exhibits robust amanta-
dine inhibition of currents at pH ranges where this construct is otherwise
active and (at pH 2.4) where amantadine sensitivity by the wild-type
protein begins to be lost, suggesting a similar, pH-tunedmode of inhibi-
tion amongst the two constructs and serving as an important internal
control for demonstration of the speciﬁcity of the unnatural amino
acid substitution.
In summary, our ﬁndings support the growing body of evidence that
proton transport through M2 takes place predominantly via a pH-
activated histidine shuttle mechanism. Speciﬁcally the mechanism is
deﬁned by theHis37 side chain pKa thatmay vary amongst an ensemble
of transmembrane bundle conformations and as a function of tetrad
protonation state for successive His37 sites. The kinetic cycle involves
extraviral protonation of His37 imidazole by adjacent hydrogen bonded
water molecules, and deprotonation on the extraviral aspect of the
protein, with a side chain ring ﬂip. Furthermore, at least for this close
analog of His37, we can conclude that tautomer exchange is not re-
quired for the kinetic mechanism of conduction.
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